Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28627303 | 1.00 | ABCB1 (0.35) | ABCB1HRH3MAOAACHEPTPRB | |
| SCHEMBL28627304 | 1.00 | ABCB1 (0.35) | ABCB1HRH3MAOAACHEPTPRB | |
| SCHEMBL17728802 | 1.00 | ABCB1 (0.35) | ABCB1HRH3MAOAACHEPTPRB | |
| SCHEMBL12880125 | 1.00 | ABCB1 (0.35) | ABCB1HRH3MAOAACHEPTPRB | |
| SCHEMBL31232627 | 1.00 | ABCB1 (0.35) | ABCB1HRH3MAOAACHEPTPRB | |
| SCHEMBL17739798 | 1.00 | ABCB1 (0.35) | ABCB1HRH3MAOAACHEPTPRB | |
| SCHEMBL17728803 | 1.00 | ABCB1 (0.35) | ABCB1HRH3MAOAACHEPTPRB | |
| SCHEMBL22045464 | 0.90 | ABCB1 (0.44) | ABCB1MAOAPTPRB | |
| SCHEMBL20586403 | 0.90 | ABCB1 (0.44) | ABCB1MAOAPTPRB | |
| SCHEMBL20529469 | 0.90 | ABCB1 (0.44) | ABCB1MAOAPTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218391-B1 | TUBULYSIN ANALOGS AND METHODS OF MAKING AND USE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-09 | — | — | EP | disclosed |
| US-10077287-B2 | Tubulysin analogs and methods of making and use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-09-18 | — | — | US | disclosed |
| US-20160130299-A1 | TUBULYSIN ANALOGS AND METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130299-A1 | TUBULYSIN ANALOGS AND METHODS OF MAKING AND USE | CCNY, CDC45, TPX2 | ABCB1 2491/4885HRH3 280/4885MAOA 4506/4885 |
| US-10077287-B2 | Tubulysin analogs and methods of making and use | CCNY, CDC45, TPX2 | ABCB1 2491/4885HRH3 280/4885MAOA 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.